Navigation Links
The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
Date:6/19/2008

The results of a major international clinical trial coordinated by the Montreal Heart Institute were reported today in the New England Journal of Medicine. The Atrial Fibrillation and Congestive Heart Failure Trial (AF-CHF) was a prospective, multicentre project involving patients with heart failure and atrial fibrillation. Heart failure is an important cause of death in the population and associated atrial fibrillation (a very common heart rhythm disorder) further increases the risks. The trial was launched in 2001 and enrolled 1,376 patients at 123 hospital sites in North America, South America, Europe and Israel. The project's goal was to improve treatment with the objective of reducing mortality and morbidity linked with atrial fibrillation and heart failure. Made possible by a grant of more than $6.5 million from the Canadian Institutes of Health Research (CIHR), this study was directed by Dr. Denis Roy, a cardiologist at the Montreal Heart Institute (MHI) and Chair of the Department of Medicine at the Universit de Montral, in collaboration with Dr. Mario Talajic, also a cardiologist at the MHI, and several Canadian researchers and international experts who contributed to this large-scale research project.

Methodology

Between May 2001 and June 2005, the 1,376 patients were randomly assigned to a rhythm-control strategy (where patients received electrical shocks and medication to suppress the abnormal rhythm) or a more simpler strategy of rate-control (where two common drugs, beta-blockers and digitalis, are used to prevent rapid heart rates with no specific efforts to regularize the rhythm). The primary endpoint of the study was cardiovascular mortality. Data management and analysis were performed at the Montreal Heart Institute Coordinating Center (MHICC).

Rate-control as effective as rhythm-control

The intention-to-treat analysis revealed no difference in the primary endpoint between the two groups. Cardiovascular death occurred in 182 (27%) patients in the rhythm-control group compared with 175 (25%) in the rate-control arm. Total mortality, worsening heart failure and stroke were similar between the two groups. Hospitalizations were more frequent in the rhythm-control group, many due to hospitalization for management of atrial fibrillation.

Rate-control should be the primary approach

The AF-CHF trial provides important new information concerning two widely-used treatment strategies for atrial fibrillation in patients with heart failure. The routine use of a rhythm-control strategy did not reduce the rate of death in comparison with a rate-control strategy. Furthermore, there were no significant differences in other important outcomes such as worsening heart failure or stroke. The rate-control strategy eliminated the need for repeated cardioversions and reduced rates of hospitalization. In conclusion, the results of this trial suggest that rate-control, should be considered the primary approach for patients with atrial fibrillation and congestive heart failure.

"It is now clear that the rate-control strategy offers a less complex approach for the management of atrial fibrillation and could reduce rates of hospitalization" says Dr. Denis Roy, the principal investigator.

"The result of this provocative study challenges the conventional wisdom, and shows that these patients can be conservatively managed, without repeated electric shocks. This will serve as a new goal post for future care of these patients," said Dr. Peter Liu, Scientific Director of the CIHR Institute of Circulatory and Respiratory Health.

About atrial fibrillation

Atrial fibrillation is a cardiac rhythm disorder in which the upper chamber of the heart (the atria) beats irregularly and very rapidly. Patients may experience this in the form of palpitations, shortness of breath or chest pain. This is the most common form of sustained arrhythmia. Contrary to ventricular fibrillation (originating in the ventricles or lower chamber of the heart), atrial fibrillation is rarely fatal but does require treatment as it can lead to severe discomfort, heart failure or stroke. Atrial fibrillation affects roughly 2.2 million Americans, predominantly the elderly.

About congestive heart failure

Congestive heart failure affects over 4 million Americans and the number of patients suffering from heart failure will continue to rise over the next few decades. Heart failure is a clinical syndrome where the heart is unable to pump enough blood to satisfy the organism's metabolic needs. In roughly two-thirds of cases, the dysfunction is caused by defective cardiac muscle contraction due to coronary disease and hypertension. Despite recent advances in our understanding of the physiopathology of heart failure and the development of new drugs, the prognosis remains serious. The five-year mortality rate is 50%, and heart failure is the main cause of cardiovascular hospitalizations.


'/>"/>

Contact: Valrie Gonzalo
gonzalo@videotron.ca
514-626-6976
University of Montreal
Source:Eurekalert

Related medicine news :

1. World fertility experts to meet in Montreal - IVF and IVM patients to provide first-person accounts at 14th World Congress
2. Worrell Inc. Acquires Gad Shaanan Design Operations in Montreal and San Diego
3. The Montreal Childrens Hospital of the MUHC begins search for causes of autism
4. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
5. Drug for cluster headaches may cause heart problems
6. Use of certain lipid measures not more effective in predicting coronary heart disease
7. Restricting Blood Flow May Help Heart Bypass Patients
8. Urban Smog Tough on Young Adults Hearts
9. Stanford study highlights cost-effective method of lowering heart disease risks
10. Vitamin Es lack of heart benefit linked to dosage
11. Drug That Lowers Resting Heart Rate Being Tested
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Tampa, FL (PRWEB) , ... February 17, 2017 ... ... a premier sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 ... through Wednesday, Inspirata will showcase its anatomic and molecular pathology workflow solution, as ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in the greater ... LifeNet 4 Families organization. , For more than 30 years, LifeNet 4 ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
(Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... , Feb. 17, 2017   Parker ... protecting the rights of victims injured by medical ... regulators to call for better reporting. Congress required ... Safety concerns involving power morcellators and duodenoscopes ... to investigate how hospitals report injuries and deaths ...
(Date:2/17/2017)... February 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, ... The global ablation technologies market is expected to grow at a ... The market is expected to grow at a CAGR of 9.5% ... 2016, and $9.05bn in 2026. ... How this report will benefit you Read on ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
Breaking Medicine Technology: